Roche to unveil lung, breast cancer data at ESMO 2026
Mon 06:16
Roche to unveil lung, breast cancer data at ESMO 2026 BERLIN, Oct 19 (Reuters) - Roche said on Monday it will present new late-stage trial results at the ESMO 2026 cancer meeting in Madrid, including data showing its lung cancer drug divarasib worked better than current KRAS G12C treatments.
The company will also show data that its breast cancer pill giredestrant improved outcomes without hurting patients' quality of life, and that its experimental drug Tam-Peli showed strong results in several hard-to-treat tumours.
(Reporting by Kirsti Knolle; Editing by Tom Hogue)
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey